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Abstract
Fibrinogen and fibrin play important, overlapping roles in blood clotting, fibrinolysis, cellular and matrix
interactions, inflammation, wound healing, and neoplasia. These events are regulated to a large extent by fibrin
formation itself and by complementary interactions between specific binding sites on fibrin(ogen) and extrinsic
molecules including proenzymes, clotting factors, enzyme inhibitors, and cell receptors. Fibrinogen is comprised
of two sets of three polypeptide chains termed Aα, Bβ, and γ, that are joined by disulfide bridging within the Nterminal E domain. The molecules are elongated 45-nm structures consisting of two outer D domains, each

connected to a central E domain by a coiled-coil segment. These domains contain constitutive binding sites that
participate in fibrinogen conversion to fibrin, fibrin assembly, crosslinking, and platelet interactions (e.g.,
thrombin substrate, Da, Db, γXL, D:D, αC, γA chain platelet receptor) as well as sites that are available after
fibrinopeptide cleavage (e.g., E domain low affinity non-substrate thrombin binding site); or that become
exposed as a consequence of the polymerization process (e.g., tPA-dependent plasminogen activation). A
constitutive plasma factor XIII binding site and a high affinity non-substrate thrombin binding site are located on
variant γ′ chains that comprise a minor proportion of the γ chain population. Initiation of fibrin assembly by
thrombin-mediated cleavage of fibrinopeptide A from Aα chains exposes two EA polymerization sites, and
subsequent fibrinopeptide B cleavage exposes two EB polymerization sites that can also interact with platelets,
fibroblasts, and endothelial cells. Fibrin generation leads to end-to-middle intermolecular Da to EA associations,
resulting in linear double-stranded fibrils and equilaterally branched trimolecular fibril junctions. Side-to-side
fibril convergence results in bilateral network branches and multistranded thick fiber cables. Concomitantly,
factor XIII or thrombin-activated factor XIIIa introduce intermolecular covalent ε-(γ glutamyl)lysine bonds into
these polymers, first creating γ dimers between properly aligned C-terminal γXL sites, which are
positioned transversely between the two strands of each fibrin fibril. Later, crosslinks form mainly between
complementary sites on γ chains (forming γ-polymers), and even more slowly among γ dimers to create higher
order crosslinked γ trimers and tetramers, to complete the mature network structure.

INTRODUCTION
Fibrinogen and fibrin play important, overlapping roles in blood clotting, fibrinolysis, cellular and matrix
interactions, inflammation, wound healing, and neoplasia. These events are regulated to a large extent by the
fibrin formation process and by interactions between specific sites on fibrinogen or fibrin and extrinsic
molecules such as proenzymes, clotting factors, growth factors, enzymes inhibitors, and cell receptors.
Fibrinogen molecules are elongated 45-nm structures consisting of two outer D domains, each connected by a
coiled-coil segment to a central E domain (see Figure 1). They are comprised of two sets of three polypeptide
chains termed Aα, Bβ, and γ,1 which are joined together within its N-terminal E domain by five symmetrical
disulfide bridges, one pair at position Aα 28, two pairs between Aα36 and Bβ65, and a third set between the γ8
and γ9 positions.2-4 Because these γ chain bridges are reciprocal (i.e., γ8 to γ9),5 they orient the chains in an
antiparallel manner, and this may contribute to the twofold axis of symmetry perpendicular to the long axis that
fibrinogen displays.6-8 Other non-symmetrical interchain disulfide bridges in this region form a so-called disulfide
ring.2, 4 The Aα chain consists of 610, the Bβ chain 461, and the major form of γ chain, γA, 411 residues.1 A minor
γ chain variant termed γ′, arises through alternative processing of the primary mRNA transcript,9 and amounts to
about 8% of the total γ chain population.10 γ′ chains consist of 427 residues and differ from the platelet-binding
γA chains in that the four C-terminal γA residues, AGDV, are replaced by an anionic 20-amino acid sequence that
includes two sulfated trosines.11, 12 Fibrinogen γ′ chains bind plasma factor XIII B subunits and serve thereby as a
carrier protein for the catalytic A subunits,13 but they do not bind to the platelet fibrinogen receptor, αIIbβ3.14 The
C-terminal γA chain sequence, γ400–411, however, plays a critical role in mediating platelet aggregation via the
platelet fibrinogen receptor.15-17

Figure 1 Schematic diagram of fibrinogen and fibrin showing the major structural domains, the association sites
that participate in fibrin polymerization and crosslinking, and other molecular and cellular binding interactions.

FIBRINOGEN CONVERSION TO FIBRIN AND FIBRIN ASSEMBLY
The N-terminal region of each Aα chain contains the FPA sequence, cleavage of which at Aα16R–17G by
thrombin initiates fibrin assembly18-20 by exposing a polymerization site, EA. One portion of the EA site is located
at the N-terminus of the fibrin α chain comprising residues 17 to 20 (GPRV);21 another portion is located in the
fibrin β chain between residues 15 and 42.22-25
Each EA site subsequently combines with a constitutive complementary binding pocket (Da) in the D domain of
neighboring molecules that is located between γ337 and γ379.26-28 These initial EA:Da associations result in
formation of double-stranded twisting fibrils in which fibrin molecules become aligned in an end-to-middle
staggered overlapping domain arrangement (see Figure 2).29-31 Fibrils undergo lateral associations and form
branches that result in a complex fiber network.32, 33 Two types of branching account for fibrin network
structures,34 and they both play important roles in defining clot network structure. The first type occurs when
double-stranded fibrils converge side-to-side to form the most widely appreciated fibril junction,
a tetramolecular or bilateral branch point. More extensive lateral fibril associations result in large fiber bundles
consisting of multiple fibrils and more condensed bilateral branch structures. This type of structure confers
strength and rigidity to the network fibers.

Figure 2 Schematic diagram of fibrin assembly and crosslinking. Assembly of fibrin begins with non-covalent
interactions (D:E) between the EA and Da sites (dotted lines) to form end-to-middle staggered overlapping
double-stranded fibrils (upper). Fibrils also branch and undergo lateral associations to form wider fibrils and
fibers. [Inset: critical point dried thin fibril matrix containing equilateral (arrows) and bilateral (arrowheads)
branch junctions; bar, 100 nm]. After cleavage of FPB (lower), αC domains become available for self-association
with other αC domains, thereby promoting lateral fibril associations and fiber assembly. Factor XIII or XIIIa
introduces ε-(γ-glutamyl) lysine isopeptide bonds between C-terminal γXL sites (thick lines between D domains)
to rapidly form γ dimers. γ Trimers and γ tetramers form more slowly by interfibril γ chain crosslinking, and
increase the resistance of the clot to fibrinolysis.
The second type of branch junction, termed trimolecular or equilateral, forms by the coalescence of three fibrin
molecules that connect three double-stranded fibrils of equal widths (Fig. 2). Equilateral branches probably form
with greater frequency when fibrinopeptide cleavage is relatively slow. Under these conditions, especially during
the early phases of fibrin assembly, relatively large amounts of fibrin intermediates lacking a single FPA (des-A
fibrin)35, 36 are formed. The availability and persistence of intermediate fibrin units very likely promotes higher
degrees of equilateral branching as partially converted des-A fibrin intermediates search for complementary
partners with only partial success. Blombäck et al.37 have shown that the architecture of fibrin networks formed
at low levels of thrombin is more branched and therefore tighter (i.e., less porous) than networks formed at high
levels of thrombin. The type of network architecture that characterizes the tight fibrin network is entirely
consistent with the higher degree of equilateral fibril branching that occurs at low thrombin levels.38 Such
branches enhance clot elasticity.
There are two constitutive self-association sites, γXL and D:D, that participate in the fibrin or fibrinogen assembly
process.39, 40 The γXL site overlaps the crosslinking site in the C-terminal region of each γ chain. Intermolecular
association between two γXL sites promotes alignment of crosslinking sites for subsequent factor XIII- or XIIIamediated transglutamination. The D:D sites are situated at the outer portion of each fibrin(ogen) D domain
between residues 275 and 300 of the γ module.41 They are necessary for proper end-to-end alignment of
fibrinogen or fibrin molecules in assembling polymer structures, as exemplified by investigation of a
dysfibrinogenemia, Tokyo II (γR275C),40 which had defective D:D contacts. Crosslinked Tokyo II fibrinogen
formed disorganized fibril structures despite the fact that γ chain crosslinking at the γXL site had proceeded at a
normal rate. Tokyo II fibrin networks were characterized by increased fiber widths, tapering fibers, and an

increased level of fiber branching, which evidently resulted from slower fibrin assembly and inaccurate end-toend positioning of assembling fibrin monomers.

MOLECULAR AND CELLULAR INTERACTIONS FOLLOWING FIBRINOPEPTIDE B
CLEAVAGE
FPB (Bβ1–14) release occurs more slowly than the release of FPA18-20 and exposes an independent
polymerization site, EB,42 beginning with β15–18 (GHRP).21 EB is utilized through interactions with a constitutive
complementary Db site located in the C-terminal β chain segment of the D domain.28, 42, 43 The EB:Db interaction is
not absolutely required for lateral fibril and fiber associations, but it contributes to this process through
cooperative interactions resulting from alignment of D domains in the assembling polymer.42 Polymerization of
des BB-fibrin results in the same type of fibril structure as occurs with des AA-fibrin,38 but the clot strength is
lower than that of des AA-fibrin.42
The αC domain originates in the D domain at residue 111 and terminates at its C-terminus, Aα610.1 Fibrin clots
formed from circulating fibrinogen molecules such as fibrinogen catabolite fractions I-6 to I-9, which lack Cterminal portions of the αC domain, display a prolonged thrombin time, reduced turbidity, and produce thinner
fibers.44-46 In fibrinogen, the αC domains tend to be non-covalently tethered to the E domain,6, 47, 48 but
dissociate from it following FPB cleavage.47, 48 This event evidently makes αC domains available for interaction
with other αC domains, thereby promoting lateral fibril associations and network assembly (Fig. 2).
In addition to its role in mediating fibrin assembly, the β15–42 sequence binds heparin49, 50 and participates in
cell-matrix interactions. β15–42 mediates platelet spreading,51 fibroblast proliferation,52 endothelial cell
spreading, proliferation and capillary tube formation,50, 52-54 and release of von Willebrand factor.55, 56 Binding to
endothelial cells is mediated by the endothelial cell receptor, VE-cadherin.54

CROSSLINKING OF FIBRINOGEN AND FIBRIN
The C-terminal region of each fibrinogen or fibrin γ chain contains a single crosslinking site at which factor XIII or
XIIIa catalyzes the formation of γ dimers39, 57-59 by incorporating intermolecular reciprocal ε-(γ-glutamyl)lysine
bridges between a donor γ406 lysine of one chain and a glutamine acceptor at γ398/399 of another.60-62 The
same type of intermolecular cosslinking occurs more slowly among several amine donor and lysine acceptor
sites in Aα or α chains,32, 65 and small amounts of internally crosslinked α-γ chain heterodimers are found in
plasma fibrinogen molecules.66 In addition to γ dimers, higher order forms of crosslinked γ chains, namely γ
trimers and γ tetramers, evolve slowly.32, 59, 65, 67 Because there is only a single donor lysine residue at
γ406,60, 62, 63, 68 it is safe to assume that trimeric and tetrameric structures form through utilization or reutilization
of that same residue.

THE ALIGNMENT OF γ CHAIN PAIRS IN CROSSLINKED FIBRINOGEN OR FIBRIN
POLYMERS
Interactions between D and E domains in an assembling fibrin polymer facilitate the antiparallel intermolecular
alignment of γ chain pairs at the γXL site, thereby accelerating the rate of XIIIa-mediated crosslinking.58, 39 The
orientation of these C-terminal γ chain pairs within an assembled and crosslinked fibrin or fibrinogen polymer
has been at issue for some time. On the basis of evidence to be recited below, we believe that crosslinked γ
chains become situated transversely between the D domains of opposing strands of a fibrin or fibrinogen fibril
(see Figure 3). Despite the strength of this evidence, many others hold to the belief that these crosslinked
regions are positioned across the distal ends of two linearly aligned molecules within a fibril strand in a socalled DD-long or end-to-end arrangement. It is valuable to summarize the evidence for these differing views,

beginning with the end-to-end argument. Soon after the report by Fowler et al.,69 which involved the
demonstration of XIIIa-crosslinked fibrinogen dimers disposed end-to-end, it became almost axiomatic that
crosslinked γ chains in assembled fibrin fibers were oriented in the same way. The DD-long model later drew
support from observations on crosslinked fibrin degradation products that had been unfolded in acetic
acid70 and from the appearance of end-to-end crosslinked fibrinogen molecules that had been dissociated in
acetic acid or that had been assembled on a fibrin fragment E template.71 The conclusions drawn in both studies
were ambiguous because they were based upon the appearance of acetic acid dissociated polymer structures
that are known to become unfolded under such conditions.72 In addition, side-to-side fibril associations, as well
as end-to-end associations occurred in the fibrin E-fibrinogen study,71 making it possible for either end-to-end or
transverse crosslinking to occur. At most, these studies show that end-to-end positioning of crosslinked γ chains
occurs under circumstances that are not closely related to those in assembled fibrin.

Figure 3 Schematic diagram of assembled fibrin molecules illustrating the intermolecular arrangements in a
fibril. The positioning of the γXL sites in transverse or end-to-end orientations is shown, as is the C-terminal
sequence of the critical residues of the γA chain crosslinking site. The emergence of the C-terminal portion of the
γ chain from the middle of the γ module is consistent with recent crystallographic reports.41, 73 Reproduced from
Mosesson et al.78
The idea of a DD-long arrangement has also gained inferential support from evaluation of D domain crystal
structures,41, 73 even though in the studies cited the γ chain region involved in crosslinking had not been
visualized. Nevertheless, from the observed folding of structures comprising the D domain crystals and from
calculation of the distances that each γ chain would presumably be required to traverse in order to become
engaged with another γ chain, these groups concluded that transverse crosslinking could not occur in fibrin.
These calculated discrepancies do not amount to a cohesive argument against the transverse crosslinking
arrangement since they do not directly contradict the experimental evidence that provides proof for such
structures in fibrin (vide infra). They should serve instead as a stimulus to reconcile potential differences
between structures found in D domain crystals and those that enable transverse crosslinking to take place in
fibrin. In this connection, Medved et al.74 recently reported that the middle strand (i.e., γ381 to γ390) of a fivestranded β sheet structure in the γ module of D domain crystals, immediately preceding the sequence
containing the γXL site, can be displaced without disrupting the compact structure of the γ module. This suggests
that the γXL region in the fibrin polymer can be pulled out and thus become more extended, a behavior that
might explain how transverse crosslinking takes place.
Several investigations relating to fibrin crosslinking, beginning with one by Selmayr et al.,75 point directly to
transverse positioning of γ chains in crosslinked fibrin fibrils. These investigators found that in the presence of
XIIIa, fibrinogen molecules formed a γ chain-crosslinked complex with immobilized fibrin, an arrangement that
was interpreted as having arisen through transverse γ chain orientation. In later studies,76 this group showed
that crosslinked double-stranded fibrin fibrils were not depolymerized by 3 M urea, a solvent that can otherwise
disrupt D:E interactions. The observation reinforced the conclusion that crosslinked γ chains were positioned

transversely in fibrin networks. In follow up studies triggered by the Selmayr reports,a electron microscopic
analyses of crosslinked fibrinogen polymers demonstrated double stranded fibrils that had formed via
crosslinked γ chains traversing the fibril strands39 (see Figure 4). More focused evidence for transverse
crosslinking came from a study demonstrating that mixtures of fibrin plus plasmic fragment D produced XIIIacrosslinked D:fibrin:D complexes that must have come about through transverse γ chain
positioning.72 Moreover, EM images of D:fibrin:D complexes in that same study showed folding of the
crosslinked molecular complex into transverse positions that could readily be converted to end-to-end
positioning in the presence of dilute acetic acid, a solvent that disrupts non-covalent intermolecular fibrin
associations. More recently, high resolution electron microscopy of gold-cadaverine-labeled γ chains in
fibrinogen molecules or fibrin fibrils demonstrated that C-terminal γ chain regions are most often oriented
toward the center of the molecule, suitably aligned for transverse crosslinking.78 The most recent and perhaps
most convincing evidence for transverse γ chain crosslinking, was obtained from analyses of the type and
amount of radioactive γ dimers produced in crosslinking mixtures of fibrinogen 1 (γA, γA) and 125I-labeled fibrin 2
(γA, γ′) (see Figure 5) or the converse, fibrin 1 and 125I-fibrinogen 2 (not shown).77 In the example shown, had
DD-long crosslinking occurred, radioactive γ dimers would not have formed, whereas transverse crosslinking
would have resulted in a 1:1 mixture of radioactive γA-γA and γA-γ′ dimers. In fact, a mixture of radioactive γ
dimers in a 1:1 ratio was found as predicted for transverse crosslinking. In summary, although the possibility
remains that some degree of end-to-end crosslinking may occur in fibrin, in sifting through all available
information, we can find no durable evidence for this type of crosslinking in assembled fibrin networks. Instead,
the evidence points to transverse crosslinking as the predominant, if not the only, crosslinking arrangement in
fibrin.

Figure 4 Scanning transmission electron microscope (STEM) image obtained from a sample of a XIIIa-fibrinogen
crosslinking mixture. The micrograph shows a double-stranded γ chain-crosslinked fibrinogen fibril. The
arrangement of the molecules comprising the fibril is drawn schematically. Filamentous structures connecting
the fibril strands (arrows), probably represent transversely crosslinked γ chains. There are numerous noncrosslinked fibrinogen molecules and occasional oligomers in the field. Bar, 100 nm. Reproduced from
Mosesson et al.39

Figure 5 One of two protocols that were used to evaluate end-to-end versus transverse XIIIa-mediated
crosslinking in a mixture of fibrinogen 1, 125I-fibrin 2, and XIIIa (upper) and the results of autoradiography of a
SDS-PAGE gel (lower). Modified from Siebenlist et al.77

FIBRINOGEN AND FIBRINOLYSIS
Tissue-type plasminogen activator (tPA)79 circulates in blood and is synthesized by vascular endothelial
cells.80 tPA-mediated plasminogen activation is markedly accelerated in the presence of fibrin, whereas there is
little effect in the presence of fibrinogen.81, 82 The stimulatory event is promoted not only by fibrin polymers, but
also by XIIIa-crosslinked fibrinogen fibrils.83 Plasminogen activation occurs through tPA binding to fibrin followed
by the addition of plasminogen to form a ternary complex.81 Two sites in fibrin are involved in enhancement of
plasminogen activation by tPA, Aα148–160 and γ312–324.84, 85 These sites are cryptic in fibrinogen but become
exposed as a consequence of non-covalent D:E interactions in assembling fibrin fibrils. These associations induce
conformational changes in the D region that result in exposure of tPA- and plasminogen binding sites, and the
exposure is reversed after the complex dissociates.86 There is a single high affinity plasminogen binding site in
fibrinogen or fibrin,87 and it seems to be located in the distal portion of the αC domain.88 Proteolytic cleavage by
plasmin creates numerous additional lysine binding sites,89, 90 thereby enhancing fibrinolysis by increasing the
accumulation of plasminogen.
Other plasma proteins, notably α2-antiplasmin, are crosslinked to fibrin α chains91 at Aα303.92 Although it has
been recognized for many years that there is a potent antiplasmin activity that is bound to fibrinogen,93 the
specific entity in fibrinogen accounting for that activity had not been identified. Recently, however, Siebenlist et
al., using an immunochemical technique, directly demonstrated the presence of covalently bound α2antiplasmin in normal fibrinogen as well as in a dysfibrinogenemic fibrinogen, Cedar Rapids (γR275C).94 The
transglutaminase activity responsible for the effect is probably plasma factor XIII, which has considerable
constitutive fibrinogen crosslinking potential.59 The presence of α2-antiplasmin on fibrin(ogen) enhances
resistance to fibrinolysis,95 but some other protein bound to fibrin(ogen) might also contribute to this effect.
That is, in addition to α2-antiplasmin, PAI-2, an inhibitor of plasmin generation by urokinase or tPA, can also be
crosslinked to fibrin at sites in the Aα chain that are remote from the Aα303 site for α2-antiplasmin,96, 97 thus
amplifying fibrin resistance to lysis.
Lipoprotein(a) is a highly atherogenic lipoprotein complex formed from apolipoprotein(a) that is disulfide bound
to the apolipoprotein B-100 moiety of LDL. LP(a) binds to plasmin-degraded fibrin and fibrinogen,98 competes
with plasminogen for binding sites in fibrin(ogen),99, 100 and becomes crosslinked to fibrinogen in the presence of

XIIIa,101 effectively increasing the local concentration of LP(a) within the clot. The presence of this lipoprotein
complex on fibrin(ogen) has an important negative effect on fibrinolysis.99, 100 (Also see HRGP.)

THROMBIN BINDING TO FIBRIN AND FIBRINOGEN
Thrombin binding to its substrate fibrinogen is mediated through an anion-binding fibrinogen recognition
exosite in thrombin.102, 103 Binding at the substrate recognition sites in the E domain leads to proteolytic cleavage
and release of FPA and FPB. In addition to fibrinogen-substrate binding, fibrin also has a significant thrombin
binding potential that was highlighted more than 55 years ago by Walter Seegers, and which he termed
antithrombin I.104, 105 Little more has been written on this topic from the standpoint of its relevance to thrombin
metabolism and the pathophysiology of thrombophilia, but we do know that dysfibrinogenemic subjects with
defective thrombin binding to fibrin have strikingly thrombophilic phenotypes.106
Antithrombin I activity is defined by two classes of non-substrate thrombin binding sites in fibrin,107, 108 one of
low affinity in the E domain, and the other of high affinity in D domains of fibrin(ogen) molecules containing a γ
chain variant termed γ′ (γ′1–427L).108 γ′ chains contain a unique 20 residue highly anionic, tyrosine-sulfated Cterminal sequence (Fig. 1),11, 12 and differ from γA chains, which instead contain a C-terminal platelet-binding
sequence (γA400–411V).109 Low affinity thrombin binding evidently reflects residual aspects of fibrinogen
substrate binding, and both N-terminal portions of α chains (α27–50) and β chains (β15–42) contribute to their
formation.24, 108, 110, 111 The high affinity thrombin binding site in fibrin(ogen) is situated exclusively in the Cterminal aspect of γ′ chains (γ1–427L) between residues 414 and 427. Sulfated tyrosine residues at γ′418 and
γ′422 significantly increase the thrombin binding affinity.12
There is good reason to believe that antithrombin I activity plays an important role in modulating thrombin
activity. Dysfibrinogenemic subjects manifesting defective non-substrate thrombin binding develop severe
thromboembolic disease,106 most notably fibrinogens New York I (des Bβ9–72)22, 112 and Naples I (Bβ A68T).113115
Fibrinogen New York I was associated with recurrent deep venous thrombosis and fatal pulmonary
embolism.112 Two homozygous members of the Naples I kindred experienced occlusive arterial strokes at an
early age, whereas a third homozygous family member suffered DVT following abdominal surgery.116 In addition
to the reports cited above, recent in vitro experiments indicate that thrombin generation in recalcified
afibrinogenemic plasma117, 118 and in reptilase-defibrinated plasma118 is significantly higher than in normal
fibrinogen-containing plasma. Repletion of afibrinogenemic plasma with fibrinogen restores thrombin
generation to normal. Fibrinogen 2, which contains both high and low affinity thrombin-binding sites has a more
profound normalizing effect than fibrinogen 1 (low affinity site only).117 The connection between antithrombin I
activity and thrombotic disease remains to be more fully explored.

INTEGRIN BINDING SITES
Fibrinogen contains two integrin binding sites at Aα95–98 (RGDF) and at Aα572–575 (RGDS).1 Many cellular
interactions with fibrinogen and fibrin occur through binding to one or both of these recognition sequences. In
addition to the ability of RGD sites to bind to platelet αIIbβ3 and compete for binding with the γA400–411
sequence,120, 121 αVβ3 integrins on endothelial cells,122 melanoma cells,123 and fibroblasts124 also mediate RGDdependent fibrinogen binding. There are other integrins on endothelial cells or fibroblasts that bind to
fibrin(ogen) RGD sites.125, 126
The leukocyte integrin CD 11b/CD18 (αMβ2, Mac-1) is a high affinity receptor for fibrinogen on stimulated
monocytes and neutrophils that has been implicated in the inflammatory response. αMβ2 has been localized
within the fibrinogen D domain at a site corresponding to the confluence of γ190–202 and γ377–395, which
form two antiparallel β strands127 (Fig. 1). It is valuable to recall that the γ381 to γ390 segment may undergo
significant conformational rearrangements.74

OTHER BINDING INTERACTIONS
There are numerous examples of proteins that interact with fibrinogen or fibrin. The listing below is not
intended to be exhaustive, but coupled with binding interactions covered elsewhere in this article, it reinforces
the notion that fibrin(ogen) helps to orchestrate its own physiological destiny. Plasma fibronectin binds to the
Aα chain of fibrinogen in its C-terminal region, since fibrinogen molecules lacking this part of the molecule do
not interact with fibronectin.128 Crosslinking of fibronectin to fibrin is mediated by factor XIIIa91, 129 between
several potential lys residues in the fibrin α chain130 and mainly gln-3 of fibronectin.131 Fibroblast growth factor2 (FGF-2, bFGF) binds to fibrinogen132 and is able to potentiate endothelial cell proliferation.133 Furthermore,
binding to fibrinogen protects it from proteolytic degradation.134 Another growth factor, insulin-like growth
factor-1 (IGF-1), becomes bound to insulin-like growth factor-binding protein-3 (IGFBP-3) which itself binds
directly to fibrinogen or fibrin. IGF-1 participates in the wound healing process by stimulating stromal cell
function and proliferation.135
A vitamin K-dependent clotting factor, Xa, has been shown to bind to fibrin and to fibrin/fibrinogen degradation
products.136 Xa bound specifically to a peptide corresponding to Aα 82D to 123K, a site that is located between
the E and D domains, and quite distinct from the thrombin binding sites. Tissue factor pathway inhibitor binds to
fibrin via a C-terminal region that is rich in Arg and Lys residues, but the location of the binding site in fibrin has
not been determined.137Gelsolin is an actin-binding plasma protein that severs actin filaments, and that has been
shown to bind to the fibrin clot.138
Histidine-Rich Glycoprotein is a plasma and platelet protein that binds specifically to fibrinogen and fibrin.139 A
high proportion of HRGP circulates as a complex bound to the lysine binding site of plasminogen and this
serves to reduce the effective plasminogen concentration, inhibit binding of plasminogen to fibrin, and
retard fibrinolysis in vitro.140 The physiological relevance of this effect has been
questioned.141 Nevertheless, both high plasma levels of HRGP,142, 143 or HRGP deficiencies,144, 145 are
associated with venous thromboembolism.
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Footnotes
M.W.M became interested in this problem as a member of the Scientific Review Committee for Professor Gert
Müller-Berghaus' research group in Giessen, Germany, during which he had the opportunity of reviewing and
discussing Eberhard Selmayr's experiments. These interactions stimulated our later interests in this subject.
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